International Journal of Ophthalmic PathologyISSN: 2324-8599

Reach Us +1 850 900 2634
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Research Article, Int J Ophthalmic Pathol Vol: 1 Issue: 2

Interleukin-11: A Novel Agent in Retinal Ischemia-Reperfusion Injury

Tamer Demir1, Azat Alinak1, Ahmet Godekmerdan2, Burak Turgut1* and Nesrin Demir2
1Fırat University School of Medicine, Department of Ophthalmology, Elazığ, Turkey
2Fırat University School of Medicine, Department of Immunology, Elazığ, Turkey
Corresponding author : Burak Turgut
Associate Professor of Ophthalmology, Firat University School of Medicine, Department of Ophthalmology, Elazig, Turkey
Tel: +904242333555; Fax: +904242388096
E-mail: [email protected]
Received: October 31, 2012 Accepted: December 07, 2012 Published: December 14, 2012
Citation: Demir T, Alinak A, Godekmerdan A, Turgut B, Demir N (2012) Interleukin-11: A Novel Agent in Retinal Ischemia-Reperfusion Injury. Int J Ophthalmic Pathol 1:2. doi:10.4172/2324-8599.1000104

Abstract

Objective: To investigate the protective effect of recombinant human IL-11 (rhIL-11) administered in a systemic manner on retina tissue during ischemia/reperfusion (I/R) injury in a guinea pig model.

Materials and Methods: An experimental study in retinal I/R. Placebo, ischemia/sham, ischemia/rhIL-11 groups including five animals in each were formed from male albino guinea pigs. Retinal ischemia was induced by cannulating the anterior chambers and lifting the bottle to a height of 205 cm for 90 Min in the sham and ischemia/rhIL-11 groups. The ischemia/sham and ischemia/rhIL-11 groups received 0.1 cc of a saline solution and 5 μg/kg/day rhIL-11 intraperitoneally one hour before the ischemic insult and during two days of reperfusion, respectively. The guinea pigs were sacrificed for biochemical analysis and the levels of tumor necrosis factor alpha (TNF-α), transforming growth factor beta (TGF-β) and interleukin-6 (IL-6) in retina were analyzed with ELISA. Mann–Whitney-U and Kruskal–Wallis tests were used for statistical analysis.

Results: The mean TNF-α level of the sham group was statistically significantly higher than that of the placebo group (p=0.008). The mean TNF-α levels of the placebo and ischemia/rHIL-11 groups were significantly different (p=0.008). The mean retinal TNF-α level of the ischemia/rHIL-11 group was statistically significantly lower than that of the sham group (p=0.008). The mean retinal TGF-β level of the sham group was statistically significantly higher than that of the placebo group (p=0.008). However, the mean retinal TGF-β levels of the placebo and ischemia/rHIL-11 groups were not statistically significantly different (p=0.690). The mean retinal TGF-β level of the ischemia/rHIL-11 group was statistically significantly lower than that of the sham group (p=0.032). The mean retinal IL-6 level of the sham group was significantly higher than that of the placebo group (p=0.008), while there was no statistically significant difference between the placebo group and ischemia/rHIL-11 group for retinal IL-6 levels (p=1.00). The mean retinal IL-6 level of the ischemia/rHIL-11 group was significantly lower than that of the sham group (p=0.008).

Conclusion: rhIL-11 treatment reduces the levels of TNF-α, IL-6 and TGF-β in the retina of the ischemia/reperfusion-injured guinea pig retinas.

Keywords: Retinal ischemia/reperfusion injury; Recombinant human IL-11; TNF-α; IL-6; TGF-β

Track Your Manuscript

Share This Page